Table 1.
Summary of ART history and most recent regimen prior to switch (N = 443).
| ART history | n (%) | |
|---|---|---|
| Historical ARV resistance | Any | 29 (6.5) |
| None | 414 (93.5) | |
| Time on ART | <5 years | 124 (28.0) |
| 5–10 years | 119 (26.9) | |
| >10 years | 200 (45.1) | |
| Number of previous ART regimens | ≥5 | 88 (19.9) |
| 3–4 | 125 (28.2) | |
|
|
1–2 |
230 (52.0) |
|
Most recent ART regimen |
|
n (%) |
| Time on prior therapy | <2 years | 242 (54.6) |
| 2–5 years | 81 (18.3) | |
| >5 years | 120 (27.1) | |
| Single-pill regimen | – | 50 (11.2) |
| Prior two NRTIa,b | ABC/3TC | 300 (67.7) |
| TDF/FTC | 119 (26.9) | |
| AZT/3TC | 5 (1.1) | |
| NRTI sparing | 5 (1.1) | |
| Prior core agenta,c | INSTI | 258 (58.2) |
| NNRTI | 118 (26.6) | |
| PI | 91 (20.5) | |
| EI | 2 (0.5) | |
| MI | 1 (0.2) | |
| Prior DTG-basedregimena | DTG + ABC/3TC (alone) | 165 (37.2) |
| Non DTG-based regimen | 242 (54.6) |
ABC/3TC: abacavir/lamivudine; ART: antiretroviral therapy; ARV: antiretroviral; AZT/3TC: zidovudine/lamivudine; DTG: dolutegravir; EI: entry inhibitor; INSTI: integrase strand transfer inhibitor; MI: maturation inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; TDF/FTC: tenofovir/emtricitabine.
aMost recent regimen before DTG/ABC/3TC.
bIncludes patients on single-pill regimens containing the combination NRTI; 14 patients had alternative combination NRTIs or a single NRTI in their regimen.
cSome patients were on multiple core agents.